Ryan J. Sullivan

Active 1999–2025

258
Papers
46,334
Citations
93
h-index
239
i10-index

Citations

Citations per year for Ryan J. Sullivan1999: 1 citations2000: 4 citations2001: 6 citations2002: 3 citations2003: 9 citations2004: 6 citations2005: 10 citations2006: 10 citations2007: 9 citations2008: 9 citations2009: 8 citations2010: 13 citations2011: 10 citations2012: 20 citations2013: 105 citations2014: 183 citations2015: 212 citations2016: 243 citations2017: 450 citations2018: 550 citations2019: 1,832 citations2020: 2,648 citations2021: 2,893 citations2022: 2,798 citations2023: 2,168 citations2024: 3,645 citations2025: 2,019 citations2026: 61 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 7,010 citing papers, 28.2% of this breakdownChina: 3,520 citing papers, 14.2% of this breakdownUnited Kingdom: 1,368 citing papers, 5.5% of this breakdownGermany: 1,333 citing papers, 5.4% of this breakdownItaly: 1,190 citing papers, 4.8% of this breakdownFrance: 1,026 citing papers, 4.1% of this breakdownAustralia: 800 citing papers, 3.2% of this breakdownCanada: 714 citing papers, 2.9% of this breakdownSwitzerland: 685 citing papers, 2.8% of this breakdownJapan: 668 citing papers, 2.7% of this breakdownNetherlands: 658 citing papers, 2.6% of this breakdownSpain: 647 citing papers, 2.6% of this breakdown
0%28.2%Other 21%

Fields

  • Medicine59.4%
  • Biochemistry, Genetics and Molecular Biology26.1%
  • Immunology and Microbiology9.6%
  • Engineering1.4%
  • Neuroscience0.7%
  • Computer Science0.5%
  • Other2.3%

Topics

  • Cancer Immunotherapy and Biomarkers13.7%
  • Immunotherapy and Immune Responses5.5%
  • CAR-T cell therapy research5%
  • Immune Cell Function and Interaction3.6%
  • Single-cell and spatial transcriptomics3.5%
  • Melanoma and MAPK Pathways3.2%
  • Other65.5%

Coauthors

All papers

Open in search
  1. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dennie T. Frederick, Judit Jané‐Valbuena, Charles H. Yoon, Orit Rozenblatt–Rosen, Alex K. Shalek, Aviv Regev, Levi A. Garraway - Science 2016 cited by 5,391

  2. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jennifer A. Wargo, Genevieve M. Boland, Ryan J. Sullivan, Gad Getz, Nir Hacohen - Cell 2018 cited by 2,103

  3. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2018 cited by 2,609

  4. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michelle Brown, Praveen Aanur, Robert Meehan, Tal Zaks - The Lancet 2024 cited by 739

  5. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Israel Cañadas, Bastian Schilling, Adam N.R. Cartwright, Adrienne Luoma, Shruti Malu, Patrick Hwu, Chantale Bernatchez, Marie-Andrée Forget, David A. Barbie, Alex K. Shalek, Itay Tirosh, Peter K. Sorger, Kai W. Wucherpfennig, Eliezer M. Van Allen, Dirk Schadendorf, Bruce E. Johnson, Asaf Rotem, Orit Rozenblatt–Rosen, Levi A. Garraway, Charles H. Yoon, Benjamin Izar, Aviv Regev - Cell 2018 cited by 1,482

  6. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 878

  7. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2018 cited by 1,542

  8. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James M. McFarland, Ewa Sicińska, Tyler Jacks, Ryan J. Sullivan, Geoffrey I. Shapiro, Thomas E. Clancy, Kimberly Perez, Douglas A. Rubinson, Kimmie Ng, James M. Cleary, Lorin Crawford, Scott R. Manalis, Jonathan A. Nowak, Brian M. Wolpin, William C. Hahn, Andrew J. Aguirre, Alex K. Shalek - Cell 2021 cited by 614

  9. Resistance to checkpoint blockade therapy through inactivation of antigen presentation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nir Hacohen - Nature Communications 2017 cited by 1,001

  10. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque

    Authors: , , , , , , , , , , , , , , , , , , , - Circulation 2020 cited by 537

  11. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

    Authors: , , , , , , , , , , , , , , , - Cell 2020 cited by 488

  12. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

    Authors: , , , , , , , , , , , , , - Nature Medicine 2018 cited by 817

  13. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

    Authors: , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2016 cited by 1,241

  14. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 261

  15. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

    Authors: , , , , , , , , , , , , , , , , , , , , - Nature Communications 2016 cited by 572

  16. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2020 cited by 280

  17. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies

    Authors: , - Nature Reviews Drug Discovery 2021 cited by 275

  18. The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2020 cited by 226

  19. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2017 cited by 418

  20. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor–Associated Myocarditis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alexander R. Lyon, Paaladinesh Thavendiranathan, Justine V. Cohen, Kerry L. Reynolds, Michael G. Fradley, Tomas G. Neilan - Circulation 2020 cited by 267

  21. High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma

    Authors: , , , , , , , - Cancer 2018 cited by 483

  22. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Immunology 2019 cited by 333

  23. Clusters of circulating tumor cells traverse capillary-sized vessels

    Authors: , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2016 cited by 496

  24. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gagan Sahni, Carlo G. Tocchetti, Valentina Mercurio, Michael Mahmoudi, Donald P. Lawrence, Kerry L. Reynolds, Jonathan W. Weinsaft, A. John Baksi, Stéphane Éderhy, John D. Groarke, Alexander R. Lyon, Michael G. Fradley, Paaladinesh Thavendiranathan, Tomas G. Neilan - European Heart Journal 2020 cited by 343